Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Vedolizumab (Entyvio) 300mg Inj (CDM 9101371) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved June 27, 2026 , from http://ppman.hank.ai/transparency/procedure/9101371/by-state?code_type=CDM
“Vedolizumab (Entyvio) 300mg Inj (CDM 9101371) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/9101371/by-state?code_type=CDM. Accessed
June 27, 2026 .
“Vedolizumab (Entyvio) 300mg Inj (CDM 9101371) by State,” HANK Price Transparency ,
accessed June 27, 2026 ,
http://ppman.hank.ai/transparency/procedure/9101371/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
9101371 — Vedolizumab (Entyvio) 300mg Inj
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$17,500
National median
$10,412 – $17,500
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 9101371 (CDM), with interquartile range
State Median p25 p75
AL $17,500 $10,412 $17,500